AI Insight
A phase 2 clinical trial led by Sylvester Comprehensive Cancer Center demonstrated that targeted immunoPET scanning successfully identified active multiple myeloma in cases where conventional PET/CT imaging and blood tests failed to detect the disease. This advanced imaging technique could enable more precise disease mapping in multiple myeloma patients, potentially improving treatment planning and post-therapy monitoring. The research suggests that standard diagnostic methods may miss clinically significant disease activity in some patients.
Why it matters
This finding could transform how doctors diagnose and monitor multiple myeloma, potentially preventing undertreatment of patients whose disease appears inactive on standard tests but remains present. More accurate disease detection may lead to better-tailored treatment strategies and improved patient outcomes by identifying residual cancer that would otherwise go undetected.
Understand the Science
A targeted immunoPET scan detected active multiple myeloma that standard PET/CT scans and blood tests missed, a finding that could help doctors more accurately map disease, guide treatment decisions and confirm whether cancer remains after therapy. The phase 2 clinical trial was led by researchers at Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine.
Source: Targeted scan detects hidden multiple myeloma missed by standard imaging